Roivant Sciences announced Tuesday during its third-quarter financial report that it will discontinue the development of its investigational SF3B1 modulator RVT-2001, following an interim analysis of a Phase I/II study in myelodysplastic syndromes.
Biogen has disclosed in a Wednesday Securities and Exchange Commission filing that it has been served a subpoena by the U.S. Department of Justice, which is seeking more information regarding the company’s overseas operations.
A survey of 141 healthcare executives by MD Revolution showed that C-suites are expanding their budgets to establish programs that increase patient and clinician satisfaction, improve outcomes, reduce overall expenses, and unlock new revenue.
The FDA on Tuesday approved Ipsen’s Onivyde, when used in combination with three chemotherapeutic drugs, for the treatment of newly diagnosed patients with metastatic pancreatic adenocarcinoma.
Biogen misses Q4 revenue estimates on Aduhelm costs, lower MS drug sales Published: Feb 13, 2024 By Tyler Patchen BioSpace Biogen’s fourth-quarter financial results were weighed down by declining multiple […]
A review of the latest leadership moves in the pharma industry.
The U.S. CDC plans to drop its five-day COVID-19 isolation recommendations under new guidance planned by the agency, the Washington Post reported on Tuesday.
The European Commission on Monday approved Biogen’s Skyclarys (omaveloxolone) for the treatment of the rare genetic disorder Friedrich’s ataxia in patients aged 16 years and above.
A federal judge on Monday dismissed a lawsuit by a major pharmaceutical industry trade association challenging a new program that allows Medicare to negotiate prices with drug companies for selected costly drugs.
Gilead Sciences announced Monday it is acquiring CymaBay Therapeutics and its lead candidate seladelpar, an investigational treatment for primary biliary cholangitis, in a $4.3 billion deal.